Fig. 2From: Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin-treated breast cancer patients: a prospective exploratory studyChanges in suPAR, GLS, NT-proBNP, TnI, and hs-CRP during study follow-upBack to article page